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Background. A specific form of small-vessel vasculopathy—cerebral microbleeds (CMBs)—has been linked to various types of 
dementia in adults. We assessed the incidence of CMBs and their association with neurocognitive function in pediatric brain 
tumor survivors.
Methods. In a multi-institutional cohort of 149 pediatric brain tumor patients who received cranial radiation therapy (CRT) 
between 1987 and 2014 at age <21 years and 16 patients who did not receive CRT, we determined the presence of CMBs on 
brain MRIs. Neurocognitive function was assessed using a computerized testing program (CogState). We used survival analysis to 
determine cumulative incidence of CMBs and Poisson regression to examine risk factors for CMBs. Linear regression models were 
used to assess effect of CMBs on neurocognitive function.
Results. The cumulative incidence of CMBs was 48.8% (95% CI: 38.3–60.5) at 5 years. Children who had whole brain irradiation 
developed CMBs at a rate 4 times greater than those treated with focal irradiation (P < .001). In multivariable analysis, children 
with CMBs performed worse on the Groton Maze Learning test (GML) compared with those without CMBs (Z-score –1.9; 95% CI: 
–2.7, –1.1; P < .001), indicating worse executive function when CMBs are present. CMBs in the frontal lobe were associated with 
worse performance on the GML (Z-score –2.4; 95% CI: –2.9, –1.8; P < .001). Presence of CMBs in the temporal lobes affected verbal 
memory (Z-score –2.0; 95% CI: –3.3, –0.7; P = .005).
Conclusion. CMBs are common and associated with neurocognitive dysfunction in pediatric brain tumor survivors treated with 
radiation.
Keywords:  cerebral microbleeds, cranial radiation therapy, late effects of tumor therapy, neurocognitive function, pediatric brain 
tumor survivors.
Treatment with cranial radiation therapy (CRT) remains an 
integral part of pediatric brain tumor therapy despite its 
known associated morbidities, including endocrine, vascular, 
and neurological sequelae.1–6 Poor neurocognition is an impor-
tant long-term side effect of CRT and has been associated with 
poor educational attainment, less full time employment, and 
decreased household income—especially if given at a young 
age.7 Affected neurocognitive domains include attention, pro-
cessing speed, working memory, and executive function.6,8–10 
However, despite similar CRT doses, some patients demon-
strate only mild cognitive impairment, whereas others suffer 
from severe disabilities. Although other risk factors predictive 
Importance of the Study
Cranial radiation therapy (CRT) remains an integral part of pediatric brain tumor therapy. However, deficits in attention, 
working memory, and executive function are important long-term side effects of CRT. Cerebral microbleeds (CMBs) have 
been associated with dementia in adult patients, and recently their presence has been demonstrated in brain tumor survi-
vors. However, there are no published data on whether CMBs are associated with worse neurocognitive function in children 
with brain tumors. In this study, we found that CMBs are common in this population, with a cumulative incidence of 48% at 
5 years. Moreover, CMBs were associated with worse performance in tests of working memory, executive function, and verbal 
memory. CMBs may serve as an early marker of neurocognitive decline and help guide targeted interventions. Future studies 
should investigate how CMB burden evolves over time in this population and whether CMBs serve as a marker of increased 
susceptibility to radiation damage.
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of poor neurocognition besides CRT include tumor location, 
presence of hydrocephalus, and significant seizure burden,11–14 
currently we cannot predict which individuals are more likely to 
have significant neurocognitive impairment.
The underlying biological mechanisms leading to radiother-
apy-associated neurocognitive deficits have yet to be clearly 
delineated. Herein we report on the effects of a specific form of 
small-vessel vasculopathy, cerebral microbleeds (CMBs), as a 
potential biomarker for neurocognitive impairment in irradiated 
pediatric brain tumor survivors. CMBs have been associated with a 
variety of dementias in adult patients, including Alzheimer disease, 
frontotemporal dementia, and mild cognitive impairment,15–17 
as well as in a healthy aging population.18 However, there are no 
published data regarding whether presence of CMBs is associated 
with worse neurocognitive function in children with brain tumors, 
or whether the presence of CMBs could serve as an early imaging 
biomarker for children at increased risk for neurocognitive decline.
In the current study, we examined the presence of CMBs in 
pediatric brain tumor patients enrolled in the Radiation-induced 
Arteriopathy (Rad-Art) study. Within this cohort we tested the 
hypotheses that (i) CMBs are common in children undergoing 
CRT and occur relatively early after CRT and (ii) the presence of 
CMBs is associated with worse neurocognitive function.
Materials and Methods 
Patient Characteristics
Patients are part of the ongoing Rad-Art study, which is a mul-
tisite cohort study of childhood cancer survivors that began 
enrollment in 2011. Patients in the study are followed with 
prospective brain and cerebrovascular imaging and neuro-
cognitive assessments using a computerized testing tool 
(CogState).19 Inclusion criteria for case enrollment in Rad-Art 
are radiation therapy to the brain or neck, age ≤21 years at the 
time of radiation therapy, survival >1 year after diagnosis, and 
ability to undergo MRI. The study expanded in 2015 to include 
a comparison group of pediatric brain tumor patients who did 
not receive any radiation therapy. For the comparison group, 
diagnosis of the brain tumor must have occurred ≤21  years 
of age. Participating institutions include Benioff Children’s 
Hospital San Francisco and Oakland, Valley Children’s Hospital, 
and Washington University in St Louis. Appropriate institutional 
approvals were obtained, and participants consented to be 
part of this study.
This analysis is based on 149 patients (n = 133 who received 
CRT, n = 16 comparison non-CRT patients) enrolled in the Rad-
Art study between October 2011 and May 2015. Patients 
received CRT between 1987 and 2014. The final analysis 
included 126 out of 149 eligible patients (110 who received 
CRT and 16 comparison non-CRT patients). Patients without 
available MRI post-CRT were excluded (n = 23) (Fig. 1).
Data Collection
Trained research assistants used standardized data collection 
tools to perform chart abstraction at all 4 enrolling sites. Data 
integrity screens were performed to ensure internal consistency 
and correct data collection and input. We collected detailed 
demographic, clinical, and tumor and radiation related informa-
tion for each subject. Variables extracted included age at tumor 
diagnosis and at initiation of radiation therapy, radiation dose 
and field, sex, race, type of chemotherapy if any, tumor type 
and location, tumor recurrence, surgical resection, highest level 
of parent education, type of MRI, as well as presence of seizures 
and ventriculo-peritoneal (VP) shunt. Type of MRI was recorded 
and classified as iron sensitive versus non–iron sensitive. Iron 
sensitive imaging was further classified into higher sensitiv-
ity, phase-sensitive (susceptibility-weighted imaging [SWI], 
including T2* susceptibility-weighted angiography), and lower 
sensitivity (gradient recalled echo imaging and fast-field echo 
imaging). Imaging was performed on both 1.5 and 3T scanners. 
Seizures and VP shunt were classified as dichotomous variables. 
CRT dose was quantified in cGy received and location was cat-
egorized into tumor bed, whole brain, or whole brain plus spine. 
CRT to ventricular field alone was classified as tumor bed only.
MRI Evaluation
A single board-certified radiologist with certificate of addi-
tional qualification in neuroradiology (B.T.) blinded to the 
identity and clinical characteristics of the patients reviewed 
all patients’ MRI pre- and postradiation to determine the pres-
ence, number, and location of CMBs. CMBs were defined as 
previously published, specifically as discrete foci of suscepti-
bility (maximum diameter of 3 mm) which did not correspond 
to perpendicular vessels, flow voids, or surgical cavity on con-
secutive slices.20 For all CMBs identified, previous scans were 
reviewed to determine first radiographic appearance of CMBs. 
Cavernous malformations and capillary telangiectasias were 
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considered distinct lesions and not classified as CMBs. CMB 
location was classified into the following categories: frontal 
lobe, parietal lobe, temporal lobe, occipital lobe, basal gan-
glia, thalamus, internal capsule, cerebellum, or brainstem. 
MRI was performed on a clinical basis; imaging protocols dif-
fered according to institutional guidelines and year imaging 
was obtained. The minimum interval was 1 month and the 
longest interval was 120  months with a median interval of 
12 months.
Neurocognitive Outcomes
Neurocognitive outcomes were assessed using a computer-
ized neurocognitive assessment tool: CogState, which offers 
an easy-to-administer screen for cognitive impairment that 
has been validated in multiple neuropsychological and cog-
nitive studies.19,21,22 Rad-Art patients >5 years old were given 
the option to undergo the CogState battery on a yearly basis. 
Patients received age-appropriate batteries (CogState battery 
for ages 5–9 and 10+). The raw scores of the tests were con-
verted into age-adjusted Z-scores, and Z-scores were used as 
the basis for analysis in order to account for the variability in 
participants’ age. The battery tests selected for the Rad-Art 
study included the detection test (psychomotor function), 
Groton Maze Learning test (GML) (executive function), interna-
tional shopping list (verbal learning and delayed recall), iden-
tification task (attention), and one-back (working memory). 
Details of these battery tasks have been described previously 
(Supplementary Table  1).23–25 All ages had age-appropriate 
norms for each test included in the battery except for patients 
ages 5–9 years for the international shopping list tests; patients 
ages 5–9 were therefore excluded from analysis of these tests. 
A total of 10 patients were excluded. CogState testing adminis-
tration was standardized across all sites and was administered 
by trained research assistants in designated interruption-free 
locations. Patients did not receive CogState testing on days of 
neuro-imaging due to concern for the effects of anesthesia on 
performance.
Radiation Dosimetry Overlays
To determine the specific amount of radiation received by 
brain regions that later developed CMBs, we overlaid radia-
tion dosimetry plans upon patients’ MR sequences with CMBs. 
Only radiation dosimetry plans for patients with CMBs who 
received CRT at Benioff Children’s Hospital San Francisco 
and Oakland between 2009 and 2012 were available. Plans 
for patients who received CRT earlier or at outside institu-
tions were not included in this analysis due to unavailability 
of these plans. MRIs revealing CMBs were aligned with and 
overlaid upon the subject’s radiation oncology dosimetry 
treatment plans using Velocity AI image registration soft-
ware (v2.7, Varian Medical Systems) to match voxel intensity 
values.26–28 Patients’ MRIs were first registered to their radia-
tion planning CT scan using a rigid automatic match based 
on bony anatomy. The alignment of the registration was then 
visually evaluated and manual adjustment was performed 
to correct any errors in alignment. The dosimetry plan was 
then overlaid onto the registered MRI, and the median radia-
tion dose (Gy) received at each CMB location was recorded. 
Further details of the registration process have been reported 
previously.29,30
Fig. 1. Flow diagram of the recruitment and selection of the 149 study participants.
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Statistical Analyses
Pearson’s chi-square test was used to compare categorical 
demographic, tumor, and clinical characteristics of patients 
with CMBs with those without. These characteristics included 
type of cancer, chemotherapy exposure, exposure to anti-angi-
ogenic therapy, sex, race, and type of MRI. The Mann–Whitney 
test was used to analyze continuous characteristics including 
maximum brain radiation dose (cGy) and age (y). Kaplan–
Meier survival analysis techniques were used to determine the 
cumulative incidence of CMBs. The observation period for all 
patients began at the end of radiation therapy. “First appear-
ance” of CMBs was defined as the midway point between the 
date of the first MRI scan demonstrating CMB and the date of 
the previous MRI. Patients without CMBs were censored from 
the analysis at the time of their most recent MRI. The period of 
observation for patients who did not receive CRT was defined 
as the period from tumor diagnosis to most recent MRI.
We used univariate Poisson regression to identify predic-
tors of CMB development. Variables associated with CMB 
development (P < .05) were then included in a multivariable 
model. Race, sex, and age at CRT were included as a priori 
variables. Linear regression models were used to assess the 
effect of CMBs on multiple domains of neurocognitive func-
tion as assessed by CogState battery subcategory scores 
(Supplementary Table 1). Standardized Z-scores for all age 
groups were used for our regression analysis. Variables 
found to be associated with neurocognitive function in uni-
variate linear regression (P < .20) were included in a multi-
variate regression model. Race, sex, age at CRT, time from 
CRT to CogState testing, tumor recurrence or growth, and 
surgery were included as a priori variables in the multivari-
able analysis. Statistical significance was defined as P < .05.
Results
Median follow-up period was 3.6  years for all patients who 
received CRT (interquartile range [IQR], 1.4–6.8) and 5.3 years 
for comparison patients (IQR, 1.8–7.3). Median age at initiation 
of radiation therapy was 8.6 years (IQR, 5.7–12.7).
Baseline clinical and demographic characteristics of 
patients receiving CRT were not significantly different from 
those not receiving CRT (Supplementary Table 2). As expected, 
tumor type differed among those treated with CRT compared 
with those who did not: the majority of patients without CRT 
had a diagnosis of low-grade glioma or craniopharyngioma, 
while the majority of those with CRT had a diagnosis of medul-
loblastoma and ependymoma.
Cerebral Microbleeds
Fifty out of 110 children who were treated with CRT had evi-
dence of CMBs on MRIs (Fig. 2). No patients had CMBs pre-
sent on MR scans prior to CRT. None of the 16 comparison 
patients who had not received CRT had any evidence of CMBs 
at last follow-up, despite the fact that they were more likely 
to have the more sensitive imaging for CMB detection avail-
able (P = .007) and similar follow-up times (follow-up times 
of patients who received CRT versus comparison group: 3.6 
vs 5.3 y, P = .287).
Children who received CRT developed CMBs with a cumula-
tive incidence of 10.8% (95% CI: 6.1–18.7) at 1-year post-CRT 
and 48.8% (38.3–60.5) at 5 years (Fig. 3). Median latency to 
CMB development was 2.6 years postradiation (IQR, 1.3–4.3 
y). The median length of follow-up did not differ significantly 
between patients with CMBs and those without (3.2 vs 3.9 y, 
P = .313). As expected, patients with CMBs were more likely to 
Fig. 2. Representative example of CMBs. CMBs are seen on iron sensi-
tive SWI (A, C) but not conventional (B, D) T1 MRI sequences. Charac-
teristic CMBs appear as discrete foci of hypointensity on iron sensitive 
imaging. (A, B) A 13-year-old patient with a pineal germinoma treated 
at 9 years with 2400 cGy of craniospinal irradiation and boost of 4500 
cGy. Images obtained at 48 months post-CRT. (C, D) An 11-year-old 
patient with medulloblastoma treated at 7  years with 3600 cGy of 
craniospinal irradiation and 5500 cGy boost to tumor bed. Images 
obtained at 42 months post-CRT.
Fig.  3. Cumulative incidence of development of CMBs in 110 brain 
tumor survivors who received cranial radiation therapy.
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have the more iron sensitive imaging available; however, the 
total number of patients with no iron sensitive imaging in this 
cohort was very small (total n = 7) (Table 1).
Predictors of cerebral microbleed development
In the univariate analysis, whole brain irradiation, expo-
sure to chemotherapy, presence of iron sensitive imaging, 
and older age at CRT were associated with increased rate 
of CMB development (Table  2). Dose of radiation therapy 
was not significantly associated with CMB development. In 
the multivariate analysis, children with whole brain irradia-
tion developed CMBs at a rate 4.3 times greater than those 
treated with focal radiation only (P ≤ .001, 95% CI: 3.1–5.9) 
(Table  2). In order to assess if anti-angiogenic therapy 
affects CMB development, we assessed the rate of CMBs 
in children being treated with regimens including the anti-
angiogenic drug bevacizumab (n = 14). Children exposed to 
bevacizumab developed CMBs at a rate 6.2 times greater 
than those not exposed to chemotherapy (95% CI: 3.3, 11.7; 
P < .001). By contrast, children exposed to chemotherapy 
regimens not including bevacizumab developed CMBs at a 
lesser rate than those exposed to chemotherapy including 
bevacizumab (Table 2).
Number and location of cerebral microbleeds
In the 50 patients with CMBs, the total number of CMBs in 
a single patient ranged from 1 to 49 (median = 3; IQR, 1.5). 
The most common locations for CMBs were the temporal lobe 
(26 patients, 52%), parietal lobe, and cerebellum (25 patients 
each, 50%), followed by frontal and occipital lobes (22 patients 
each, 44%). Relatively few patients had lesions in the basal 
ganglia (5 patients, 10%) and brainstem (2 patients, 4%). No 
patients had CMBs in the thalamus or internal capsule. Of the 
50 patients with CMBs, 30 had follow-up MRI available 1 year 
after the study that first demonstrated CMBs. Of these 30 
patients, 17 (57%) had no interval change in the number of 
CMBs, while 13 (43%) had interval increase in the number of 
CMBs, ranging from 1 to 43 more CMBs.
Table 1. Baseline clinical and demographic characteristics of patients who received cranial radiation therapy with CMBs compared with those 
without CMBs
CMBs (n = 50) No CMBs  (n = 60) P-valuea
Female (%) 26 (52) 24 (48) .577
Race (%) .51
White 40 (80) 46 (77)
Black 4 (8) 8 (13)
Asian 5 (10) 3 (5)
Other 1 (2) 3 (5)
Age at radiation therapy, median (range) 7.6 (1–21) 9.6 (1–20) .126
Adjuvant chemotherapy (%) 46 (92) 46 (77) .3
Anti-angiogenic chemotherapy (%) 7 (14) 7 (12) 1.
Cancer type (%) .253
Medulloblastoma 19 (38) 11 (19)
Ependymoma 9 (18) 11 (19)
Germinoma 4 (8) 7 (12)
High grade glioma 4 (8) 8 (13)
Low grade glioma 4 (8) 10 (17)
Other 10 (20) 13 (22)
Iron sensitive imaging (ISI) .17
(ISI)b (%) 1 (2) 6 (10)
No ISS 18 (36) 32 (53)
GRE/FFE 31 (62) 22 (37)
SWI
Radiation (%) .64
Craniospinal or whole brain 29 (60) 23 (41)
Tumor bed only 20 (40) 33 (59)
Maximum brain radiation, cGy median (range) 5580 (2400–6260) 5400 (2700–6674) .93
VP shunt (%) 16 (32) 16(27) .54
Seizure disorder (%) 8 (16) 10 (13) .925
Surgical resection 7 (12) 7 (16) .792
aP-values are Pearson’s chi-square test for categorical variables and the Mann‒Whitney U-test for continuous variables.
bISS, iron sensitive sequencing. ISI includes SWI and T2* susceptibility-weighted angiography, gradient-recalled echo (GRE), fast-field echo 
(FFE), and multiplanar gradient recalled imaging which utilize the difference in magnetic susceptibility of blood, iron, and calcification to 
detect the presence of iron with high sensitivity.
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Radiation dosimetry plans
A subset of 20 patients with CMBs (40%) had radiation dosim-
etry plans available. These 20 patients did not differ from the 
other 30 patients with CMBs with respect to either baseline 
patient, tumor, or treatment-related characteristics (data not 
shown). The majority of CMBs (63%) were in locations that 
received over 50 Gy of radiation, while 11% were in locations 
that received 40–49 Gy, 17% were in locations that received 
30–39 Gy, and only 9% were in locations that received 20–29 
Gy. The median time from CRT to CMB detection in this group 
was 2.5 years (range 8 mo–10 y).
Cerebral Microbleeds and Neurocognitive Function
Of the 110 patients who received CRT, 105 were eligible to 
complete the CogState assessment of neurocognitive func-
tion. Of these, 67 (64%) completed the optional assessment 
(66% of patients with CMBs and 56% of those without) at time 
of enrollment in the study. Only 15 (22%) of these 67 patients 
completed 2 or more assessments; therefore, we limited 
analysis to initial CogState assessment at time of enrollment. 
Patients who completed the assessment were not different 
from those who did not in terms of age at radiation, tumor 
type, or other baseline variables (data not shown). The median 
age at CogState administration was 14  years (IQR, 10–19; 
range 5–26 y), and the median time from CRT to CogState 
testing was 4.2  years (IQR, 2.3–6.9; range 0.5–16 y). In our 
univariate analysis of factors predicting neurocognitive perfor-
mance, variables that met the P-value cutoff of .2 for inclusion 
in the multivariate model included CMB presence, presence 
of VP shunt, seizure disorder, and highest level of education 
achieved by patients’ mothers. Time from CRT to CogState 
testing, tumor recurrence or growth, surgery, age at CRT, race, 
and sex were included as a priori variables in the multivari-
able analysis. In our multivariable analysis, presence of CMBs 
was associated with worse executive function (GML: Z-score 
−1.9; 95% CI: −2.7, −1.1; P < .001), especially when CMBs were 
located within the frontal lobes (GML: decrease in Z-score by 
2.4 points compared with patients without CMBs in the frontal 
lobe; P < .001; 95% CI: −2.9, −1.8). (Table 3).
In assessments of other aspects of neurocognitive func-
tion, including delayed recall, verbal learning, attention, and 
working memory, patients with CMBs continued to perform 
worse than patients without CMBs, with a specific effect of 
the location of CMBs on these different neurocognitive tasks. 
Patients with CMBs in the occipital lobe took the longest on the 
detection test of visual selective attention and psychomotor 
function (Z-score 2.9 points less compared with children with-
out CMBs in the occipital lobe [95% CI: –5.9, –0.3; P = .040]). On 
the “one back test” of working memory, patients with CMBs in 
the frontal lobe made the most mistakes (Z-score –1.2 points 
less than patients without CMBs in the frontal lobe, 95% CI: 
–2.0, –0.2; P = .019). On the test of verbal learning, patients 
with CMBs in the temporal lobes performed the worst (Z-score 
2 points worse than those without CMBs in the temporal lobes, 
95% CI: −3.3, −0.7; P = .005).
Discussion
Our analysis of 149 pediatric brain tumor patients followed by 
the Rad-Art study is the first to demonstrate that CMBs develop 
frequently in children who received CRT and that presence of 
CMBs is correlated with worse neurocognitive function in this 
population.
The prevalence of CMBs in a general pediatric population 
has not been reported. However, in the prospective Rotterdam 
population-based cohort study of 3979 adult subjects, CMB 
prevalence in subjects ages 45–50 was only 6.5%, while it was 
35.7% in subjects over 80 years,31 suggesting that CMBs are 
uncommon in younger populations. Previous cross-sectional 
studies of CMBs in pediatric brain tumor patients found preva-
lence rates ranging from 29% to 100%.32–34 Yeom et al showed 
Table 2. Multivariate Poisson regression analysis of predictors of CMBs
Univariate Analysis Multivariate Analysis
Characteristic Incidence Rate Ratioa P-value Incidence Rate Ratiob P-value
Radiation
Whole brain CRT vs focal 3.0 (2.3, 4.1) <.001 4.3 (3.1, 5.9) <.001
Exposure to chemotherapy
Any chemotherapy vs none 4.2 (2.4, 7.2) <.001 3.4 (2.0, 6.1) <.001
Any chemotherapy + bevacizumab vs none 8.5 (4.5, 15.9) <.001 6.2 (3.3, 11.7) <.001
Age at CRT, each additional 10 y 1.8 (1.3, 2.4) <.001 1.6 (1.2, 2.1) .003
Iron sensitive imagingc
T2 FFE/GRE/MPGR vs. T2 b0 23.0 (3.2, 165.5) .002 35.6 (4.9, 259.3) <.001
 SWI vs T2 b0 46.5 (6.5, 331.0) <.001 90.7 (12.6, 652.9) <.001
Maximum brain radiation, each additional Gy 0.97 (0.78, 1.2) .824
aUnivariate Poisson analysis.
bMultivariate Poisson regression analysis; race and gender were included as a priori factors.
cWe defined a participant having iron sensitive images if the MRI included the following sequences: SWI, T2* susceptibility-weighted 
angiography, gradient-recalled echo (GRE), fast-field echo (FFE), or multiplanar gradient recalled (MPGR) imaging. T2b0 was used as the least 
iron sensitive imaging and participants with T2b0 imaging only were considered to not have iron sensitive sequencing.
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that 44% (n = 93) of children with medulloblastoma receiving 
CRT had evidence of focal hemosiderin deposition (including 
CMBs and cavernous malformations) with a median follow-up 
time of 5.8 years,32 similar to another report that in 100 chil-
dren who received CRT, 33% had evidence of CMBs or cavern-
ous malformations.34 However, Peters et al found that 100% 
of children with medulloblastoma (n = 7) who received CRT 
developed CMBs at a median follow-up of 21 months.33 The 
difference in these results likely reflects differences in MRI sen-
sitivity: Yeom utilized T2* gradient recalled echo imaging with 
4- to 5-mm slices, while Peters utilized a more sensitive SWI 
sequence with 1-mm slices.34 In our study of children with 
various types of iron sensitive imaging (6% with no SWI, 45% 
with lower-sensitivity SWI, and 49% with high-sensitivity SWI), 
the cumulative incidence of CMBs in patients who underwent 
CRT was 48.8% at 5 years, while the cumulative incidence in 
comparison patients at 5 years was 0%.
In our study, craniospinal or whole brain irradiation was 
the main risk factor for the development of CMBs. While CMBs 
appeared in patients who received focal irradiation, they were 
more likely to develop in patients receiving whole brain/cranio-
spinal irradiation. Additionally, we did not find an association 
between radiation dose and CMB development. However, in 
our more detailed CRT dosimetry analysis of 20 patients, we 
demonstrated that while some CMBs occur in areas receiving 
lower doses (20–40 Gy), they most commonly appear in areas 
receiving high dose (>50 Gy). This discrepancy most likely 
reflects that we used an approximation to assess the radia-
tion dose based on the overall prescribed dose reported in the 
radiation oncology reports, while in actuality patients received 
varying doses of radiation to varying volumes of brain. Overall 
our results suggest that increased radiation dose is associ-
ated with higher risk of CMBs and that craniospinal irradiation 
or whole brain irradiation contributes to the development of 
CMBs by increasing the volume of brain at risk. This is in con-
cordance with previous reports that showed that whole brain 
irradiation is associated with higher incidence of late cerebro-
vascular complications including CMBs.32,34
Younger age at radiation has been linked to poorer neuro-
cognitive function.35 We found that older age at radiation is 
a predictor of CMB development and that both CMB develop-
ment and younger age at CRT were associated with worse 
neurocognitive function in a range of domains, including 
executive function, working memory, visual processing speed, 
and verbal memory. These results suggest that younger age 
at time of radiation therapy and CMB presence are both inde-
pendently associated with decreased neurocognitive function 
through different biological mechanisms.6,35,36 Additionally, 
we found that CMBs were associated with poorer neurocog-
nitive outcomes even in patients who were evaluated years 
after first CMB appearance, suggesting that the detrimental 
effects of CMBs are long-lasting. Given the prevalence of CMBs 
in elderly populations with dementia, our results support the 
concern that survivors of CNS tumors may experience acceler-
ated CNS aging, as reported previously.37
We found that location of CMBs is associated with domain-
specific deficits. Frontal lobe CMBs were most highly associ-
ated with poor executive function and poor working memory, 
consistent with the major role of the frontal lobe in mediating 
those functions.38,39 Similarly, occipital lobe CMBs were asso-
ciated with poor performance on the detection task, which 
measures visual selective attention, mediated by the occipital 
lobe.41,42 CMBs in the temporal and frontal lobes were asso-
ciated with poor performance in verbal learning, consistent 
with the implicated role of both lobes in learning and mem-
ory.43–45 While Yeom et al reported no correlation between IQ 
or need for special education and presence of focal hemosid-
erin deposits in childhood medulloblastoma patients, assess-
ment of a global cognitive score such as IQ might not be 
sensitive enough to detect task-specific differences.9,32,46,47 
The CogState battery includes assessment of specific cogni-
tive domains and therefore may have allowed us to capture 
more subtle effects of CMBs on neurocognition. Additionally, 
our study allowed for examination of the relationship between 
neurocognitive functional decline and CMBs in specific brain 
areas. Finally, the correlation between CMB presence and neu-
rocognitive function remained significant even after controlling 
for other factors known to be associated with neurocognitive 
function, including highest level of parental education or pres-
ence of VP shunt or seizure disorder.48,49
We found that treatment with the anti-angiogenic drug 
bevacizumab was associated with an increased rate of CMB 
formation in children. By contrast, administration of the 
anti-angiogenic drug enzastaurin with CRT was associated 
with decreased rate of additional CMB formation in adults.50 
The authors hypothesized that anti-angiogenic therapy may 
confer a possible radioprotective effect on microvasculature 
by decreasing capillary permeability and cytokine release.51 
Although we examined a different anti-angiogenic agent, our 
results support the alternative hypothesis that anti-angiogenic 
therapies may increase the susceptibility of microvasculature 
to bleeding after radiation by impairing platelet-endothelial 
function and vascular repair.52 Anti-angiogenic therapies have 
been associated with increased risk of hemorrhage in adult 
brain tumor and other cancer patients.53–55 Our results sug-
gest that bevacizumab therapy may impair vascular endothe-
lial growth factor–mediated endothelial repair after CRT and 
increase risk of CMB formation.
Limitations of this study include that CMB development was 
often assessed retrospectively, and time to development was 
therefore an estimate based on midpoint between the last nor-
mal and first abnormal MRI. Additionally, patients had disparate 
interval imaging schedules. Some patients had imaging every 
year, whereas others had imaging every 3 months. Imaging 
interval also changed in the same patients from year to year 
based on time from brain tumor treatment. Further, there was 
a lack of standardized MRI with a specific SWI protocol as well 
as variation in scanner strength across institutions and across 
time, and more sensitive imaging techniques developed over 
time. We attempted to control for these differences by report-
ing on the number of patients who received recent high qual-
ity SWI compared with patients who received no SWI or less 
sensitive T2* imaging. Additionally, although we attempted to 
control for potential neurologic comorbidities affecting neuro-
cognitive outcome by including variables such as seizure dis-
order, VP shunt, mothers’ education level, underlying genetic 
diagnoses (neurofibromatosis 1 and 2), and tumor location and 
surgery, residual confounding by other host factors may exist.
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Unfortunately, there are currently no interventions that 
have been shown to prevent the development of neurocog-
nitive deficits in survivors of pediatric brain tumors. However, 
recent studies have shown promising initial results in amelio-
rating such deficits. For example, computerized cognitive train-
ing and cognitive remediation programs, which are modeled 
after traditional brain injury rehabilitation techniques, have 
been found to improve scores in various domains, including 
working memory in patients with known cognitive deficits.56,57 
Additionally, methylphenidate has demonstrated utility in 
improving attention and social skills in brain tumor survivors.58 
Additional studies are needed to determine the efficacy of 
these interventions in patients with CMBs.
Future directions include following the Rad-Art cohort to 
determine how CMB presence evolves over time, whether 
CMBs continue to develop years after radiation, and whether 
they continue to grow or remain stable in size. Based on adult 
studies, the presence of CMBs may indicate an increased sus-
ceptibility to radiation-induced damage and possibly increased 
likelihood of late stroke.59 We also plan to follow the longitudi-
nal development and changes in neurocognitive outcomes in 
our cohort.
In conclusion, CMBs are common in survivors of pediat-
ric brain tumors who received CRT and are associated with 
neurocognitive deficits. They may hold promise as an early 
marker for neurocognitive decline and help facilitate targeted 
intervention.
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